Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.44 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TK2 | O00142 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.38 |
| ▸ | NT5M | Q9NPB1 | 1/20 | 0.38 |
| ▸ | TYMP | P19971 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALB | P02768 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11981102 | 1.00 | TK1 (0.44) | TK1RNASE1HPGDTK2BCHE | |
| SCHEMBL11981123 | 0.95 | TK1 (0.42) | TK1RNASE1HPGDTK2BCHE | |
| SCHEMBL23152977 | 0.94 | TK1 (0.41) | TK1RNASE1HPGDTK2BCHE | |
| SCHEMBL9961264 | 0.91 | TK1 (0.37) | TK1RNASE1HPGDBCHENT5M | |
| SCHEMBL17282465 | 0.90 | TK1 (0.39) | TK1RNASE1HPGDTK2BCHE | |
| SCHEMBL17356765 | 0.89 | TK1 (0.41) | TK1RNASE1HPGDTK2BCHE | |
| SCHEMBL17282463 | 0.89 | TK1 (0.38) | TK1RNASE1HPGDTK2BCHE | |
| SCHEMBL2767915 | 0.88 | RNASE1 (0.44) | TK1RNASE1HPGDTK2BCHE | |
| SCHEMBL5696121 | 0.88 | TK1 (0.39) | TK1RNASE1HPGDTK2BCHE | |
| SCHEMBL28618584 | 0.88 | TK1 (0.39) | TK1RNASE1HPGDTK2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9127280-B2 | Oligonucleotide, and therapeutic agent for dyslipidemia containing oligonucleotide as active ingredient | OSAKA UNIVERSITY (JP) | 2015-09-08 | — | — | US | disclosed |
| US-20130172402-A1 | OLIGONUCLEOTIDE, AND THERAPEUTIC AGENT FOR DYSLIPIDEMIA CONTAINING OLIGONUCLEOTIDE AS ACTIVE INGREDIENT | OSAKA UNIVERSITY (JP) | 2013-07-04 | — | — | US | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | TK1 198/4885RNASE1 77/4885HPGD 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.